Nepal Aushadhi Limited (NAL), one of Nepal's oldest government-owned pharmaceutical companies, has made an important comeback after years of financial and operational difficulties. The company reportedly recorded a net profit of around Rs. 3 crore in fiscal year 2025/26, after reporting a loss of more than Rs. 10 crore in the previous fiscal year.
The turnaround is important not only for the company but also for Nepal's pharmaceutical industry. It comes at a time when the country is trying to increase domestic medicine production and reduce dependence on imported medicines.
So, what helped Nepal Aushadhi Limited return to profit, and what could happen next?
What Is Nepal Aushadhi Limited?
Nepal Aushadhi Limited is a government-owned pharmaceutical company in Nepal. It was originally established as Royal Drugs Limited in 2029 B.S. (1972 A.D.) with technical cooperation from the British Government. The company was created with the aim of developing domestic pharmaceutical manufacturing capacity in Nepal.
Over the years, the company has produced medicines and other healthcare-related products for the Nepali market. However, it also went through a long period of financial problems, low production, and operational challenges.
Nepal Aushadhi Limited is included among Nepal's domestic pharmaceutical manufacturers listed by the Department of Drug Administration (DDA). You can learn more about the country's regulatory system in our article on Department of Drug Administration Nepal (DDA): Functions, Responsibilities and Role.
From Losses to Profit
The biggest news surrounding NAL is its reported financial turnaround.
According to reports, the company suffered a loss of more than Rs. 10 crore in the previous fiscal year. In FY 2025/26, however, it reportedly recorded a profit of approximately Rs. 3 crore. The turnaround has been described as the company's return to profit after about 25 years.
This is a major change for a company that had struggled with production and financial sustainability for many years.
A single profitable year does not necessarily mean that all of the company's problems have disappeared. NAL will still need to maintain production, control costs, ensure product quality, and compete with private pharmaceutical manufacturers.
However, the result is an encouraging sign that a government-owned pharmaceutical company can improve its performance when manufacturing, quality systems, management, and investment receive greater attention.
GMP Certification: An Important Step
One of the most important developments in NAL's recent history has been its Good Manufacturing Practice (GMP) certification.
Nepal Aushadhi Limited announced in February 2025 that it had received a GMP certificate according to WHO guidelines from the Department of Drug Administration, Ministry of Health and Population, Government of Nepal.
GMP is important in pharmaceutical manufacturing because it focuses on consistent production and quality control. It covers areas such as manufacturing processes, facilities, equipment, documentation, personnel, quality control, and hygiene.
For a pharmaceutical manufacturer, GMP certification is more than simply receiving a certificate. Maintaining GMP standards requires continuous monitoring, proper documentation, trained employees, validated processes, suitable equipment, and effective quality systems.
This is particularly important for NAL because maintaining product quality will be essential if the company wants to expand its production and compete more strongly in the domestic market.
For readers interested in pharmaceutical quality systems, our guide on CAPA in Pharmaceutical Industry: Procedure, RCA and Examples explains another important part of pharmaceutical quality management.
Expansion of Medicine Production
NAL is also working to increase the number of medicines it manufactures.
Recent reports say the company currently produces around 11 types of medicines and has plans to expand its product range to around 37 medicines. Some of the medicines being developed or planned include products for conditions such as high blood pressure, diabetes, and high cholesterol.
The expansion could be important for two reasons.
First, producing a wider range of medicines can create additional sources of revenue for the company. Second, producing more essential medicines locally could help increase the availability of domestically manufactured medicines.
However, expanding from 11 products to 37 is not a simple process. Each new medicine requires appropriate formulation development, quality testing, regulatory approval, manufacturing preparation, and market planning.
The company will therefore need strong quality assurance, quality control, research and development, regulatory affairs, and production teams to support this expansion.
If you are interested in career opportunities in these areas, you may also find our guide on Pharmaceutical Industry Jobs in Nepal 2026: B.Pharm Jobs, Salary and Career Growth useful.
Government Support and Investment
Government support has also been an important part of NAL's revival.
Reports indicate that the government has allocated around Rs. 24 crore to strengthen the company's equipment, human resources, and production capacity.
Investment is particularly important for pharmaceutical manufacturers because modern production requires suitable manufacturing equipment, laboratory facilities, quality-control systems, trained employees, and reliable infrastructure.
Investment alone, however, cannot guarantee long-term success. The company will need to use these resources efficiently and make sure that increased production is supported by actual market demand.
Why Is NAL's Return to Profit Important?
The return of Nepal Aushadhi Limited to profitability has significance beyond the company's financial statement.
1. Stronger Domestic Medicine Production
Nepal depends partly on imported medicines. Increasing local manufacturing capacity could help strengthen the country's pharmaceutical supply chain.
A stronger domestic industry can become particularly valuable during international supply disruptions, when obtaining medicines from overseas may become more difficult or expensive.
2. Support for Public Healthcare
As a government-owned pharmaceutical company, NAL has the potential to support the public healthcare system by producing selected essential medicines.
The government has also been moving toward increasing domestic production of essential medicines through NAL. Recent reports indicate plans to expand production of medicines for conditions such as hypertension and diabetes.
3. More Opportunities for Pharmacy Professionals
Growth at NAL could create opportunities for pharmacists, chemists, microbiologists, engineers, laboratory professionals, production staff, and other pharmaceutical professionals.
This is particularly relevant for pharmacy graduates looking at careers in Nepal. Our article Career Opportunities in Nepal After B.Pharm discusses different career paths in pharmaceutical manufacturing, quality control, quality assurance, regulatory affairs, hospitals, research, and other areas.
4. Encouragement for Nepal's Pharmaceutical Sector
A successful turnaround at NAL could also send a positive message to Nepal's broader pharmaceutical industry.
Nepal already has a growing number of domestic pharmaceutical manufacturers. Our article How Many Pharmaceutical Industries Are There in Nepal? provides an overview of pharmaceutical manufacturing companies operating in the country.
Challenges Ahead
Although the return to profit is encouraging, NAL still faces several challenges.
Maintaining Product Quality
Profit should never come at the expense of pharmaceutical quality. NAL will need to maintain GMP standards and strong quality-control systems as production increases.
Competing With Private Companies
Nepal's pharmaceutical market includes many private manufacturers. These companies compete on price, product availability, production efficiency, distribution, and product development.
NAL will therefore need to improve productivity and control manufacturing costs while maintaining quality.
Expanding the Product Portfolio
Increasing the number of products from around 11 to 37 will require careful planning. New products must pass the required development, testing, regulatory, and manufacturing stages before they can reach the market.
Maintaining Financial Stability
One profitable year is a positive beginning, but long-term sustainability will be more important.
NAL will need to maintain consistent sales, manage expenses, improve production efficiency, and invest wisely in future development.
What Could Be the Future of Nepal Aushadhi Limited?
The future of Nepal Aushadhi Limited will largely depend on how well it can build on its recent improvements.
GMP certification, government investment, product expansion, better production capacity, and stronger management provide a good foundation. However, these improvements need to be maintained over the long term.
If NAL successfully increases its product range while maintaining quality and controlling costs, it could become a stronger participant in Nepal's pharmaceutical industry.
It could also contribute to the country's goal of increasing domestic production of essential medicines.
Final Thoughts
Nepal Aushadhi Limited's reported Rs. 3 crore profit in FY 2025/26, after a loss of more than Rs. 10 crore in the previous year, represents an important turnaround for one of Nepal's oldest government-owned pharmaceutical companies.
The company's GMP certification, investment in infrastructure and manpower, and plans to expand medicine production have created a new opportunity for growth.
But the real success will be measured over the coming years. NAL will need to maintain product quality, improve efficiency, manage finances carefully, expand its product portfolio, and compete effectively in Nepal's pharmaceutical market.
If these challenges are managed well, Nepal Aushadhi Limited could play a much larger role in domestic medicine production and contribute to a stronger and more self-reliant pharmaceutical sector in Nepal.
References
- Nepal Aushadhi Limited. Nepal Aushadhi Limited is now GMP certified! Official company website.
- The Himalayan Times. From Rs 10 crore loss to Rs 3 crore profit: Nepal Aushadhi Limited's turnaround after 25 years. August 7, 2026.
- Department of Drug Administration, Nepal. Domestic pharmaceutical manufacturers database.
Disclaimer: This article is written for general educational and informational purposes. Financial, pharmaceutical, regulatory, and business information can change, so readers should verify important details with official sources.
